ABT-263 (Navitoclax)

Catalog No.S1001

ABT-263 (Navitoclax) Chemical Structure

Molecular Weight(MW): 974.61

ABT-263 (Navitoclax) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

Size Price Stock Quantity  
In DMSO USD 400 In stock
USD 120 In stock
USD 200 In stock
USD 370 In stock
USD 970 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 37 Publications

13 Customer Reviews

  • KP cells (A) and A549 cells (B) were treated with increasing doses of ATN-224 alone or with the BCL2 inhibitor ABT-263, and cell death (96 hours) was determined.

    J Clin Invest, 2014, 124(1): 117-28 . ABT-263 (Navitoclax) purchased from Selleck.

    Cell lines are also resistant to dual inhibition of Bcl-xL and Bcl-2 by the inhibitor ABT-263 when dosed with NSC siRNA, but co-dosing ABT-263 with Mcl-1 siRNA decreases compound IC50 similar to that observed with WEHI-539. Representative curves for MDA-MB-157 are shown in f.

    Cell Death Differ, 2015, 10.1038/cdd.2015.73. ABT-263 (Navitoclax) purchased from Selleck.

  • ABT-263 has a higher albumin binding affinity than ABT-737. The binding capacity of ABT-737 (solid lines) and ABT-263 (dotted lines) to HSA was investigated using a fluorescence polarization assay. A, to measure binding to site 2 on HSA-IIIA, dansyl sarcosine was used as a probe. In this assay the IC50 was 711 and 37μmol/L for ABT-737 and ABT-263, respectively. B, to measure binding to site 1 on HSA-IIA, dansyl L-glutamate was used as a probe. The IC50 was >1,000 and 145 μmol/L for ABT-737 and ABT-263, respectively.

    Clin Cancer Res 2010 16, 4217-4225. ABT-263 (Navitoclax) purchased from Selleck.

    Clin Cancer Res 2010 16, 4217-4225. ABT-263 (Navitoclax) purchased from Selleck.

  • Clin Cancer Res 2010 16, 4217-4225. ABT-263 (Navitoclax) purchased from Selleck.

    Clin Cancer Res 2010 16, 4217-4225. ABT-263 (Navitoclax) purchased from Selleck.

  • Clin Cancer Res 2010 16, 4217-4225. ABT-263 (Navitoclax) purchased from Selleck.

    PLoS One 2011 6, e21980. ABT-263 (Navitoclax) purchased from Selleck.

  • PLoS One 2011 6, e21980. ABT-263 (Navitoclax) purchased from Selleck.

    PLoS One 2011 6, e21980. ABT-263 (Navitoclax) purchased from Selleck.

  • Apoptosis induced by BCL2-inhibitors in P-glycoprotein expressing cells. MDCKII wild type or MDR1 cells were exposed to different concentrations of ABT-737 (C) or ABT-263 (D) for 24 h before apoptosis was assessed by flow cytometry using externalization of phosphatidylserine.

    Biochem Biophys Res Commun 2011 408(2), 344-9. ABT-263 (Navitoclax) purchased from Selleck.

     

    (A) In vitro generated  Mcl-1-deleted  Arf-/- p185+ cells stably expressing the indicated constructs were treated with indicated doses of navitoclax (ABT-263) for 24 hours after which percent viable cells were determined (propidium iodide negative cells were scored as viable). Each point represents the average of three independent experiments and the error bars denote the SEM.  p185+ Arf-/- cells serve as a control.  (B) Arf -null p185+ cells were treated with navitoclax for 24 hours at indicated doses. Lysates were immunoprecipitated with anti-BIM antibody and immune complexes were resolved and western blotted for MCL-1, BCL-2 (human specific antibody), BCL-XL, BIM, PARP and Actin (loading control). Endogenous BIM serves as the control for equal immunoprecipitation. (E&F) p185+ Arf-/- cells were treated with indicated doses of navitoclax and/or  (E) IM or  (F) DAS for 24 hours after which percent viable cells was determined. Annexin-V and PI negative cells were scored as viable. IL-7 was added to a final concentration of 20 ng/mL.

    ABT-263 (Navitoclax) purchased from Selleck.

  •  

    Human Ph+ cell lines:  (A)  OP-1 Ph+ B-ALL  (B) TOM1 Ph+ B-ALL and (C)  BV173 Ph+CML blast crisis cell lines were treated with navitoclax, imatinib (IM) or dasatinib (DAS) at indicated doses for 24 hours after which cell lysates were analyzed for expression of MCL-1, BCL-2, BCL-w, BFL-1 and BCL-XL.  For potentiation experiments, the percentage of viable cells was determined by Annexin-V and PI negativity.

    ABT-263 (Navitoclax) purchased from Selleck.

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description ABT-263 (Navitoclax) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.
Targets
Bcl-xL [1]
(Cell-free assay)
Bcl-2 [1]
(Cell-free assay)
Bcl-w [1]
(Cell-free assay)
A1 [1]
(Cell-free assay)
Mcl-1 [1]
(Cell-free assay)
<=0.5 nM(Ki) <=1 nM(Ki) <=1 nM(Ki) 354 nM(Ki) 550 nM(Ki)
In vitro

ABT-263 is structurally related to ABT-737; it is a disruptor of Bcl-2/Bcl-xL interactions with pro-apoptotic proteins. Overexpression of the prosurvival Bcl-2 family members is commonly associated with tumor maintenance, progression, and chemoresistance. [1] ABT-263 displays the protection afforded by overexpression of Bcl-2 or Bcl-xL with EC50 values of 60 nM and 20 nM, respectively. [1] A wide range of cellular activity is observed with ABT-263 having a 50% growth inhibition (EC50) of 110 nM against the most sensitive line (H146), whereas its activity in the least sensitive line (H82) results in an EC50 at 22 μM. All four cell lines with EC50 values of <400 nM (H146, H889, H1963, and H1417) are also highly sensitive to ABT-737, and the two most resistant lines (H1048 and H82) are similarly resistant to ABT-263. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
EoL-1-cell NUnkdGpyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fWZWlEPTB;MD6wNFY3QSEQvF2= MXrTRW5ITVJ?
MV-4-11 MmmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moe5TWM2OD1yLkCxOVg3KM7:TR?= NHT6dFNUSU6JRWK=
NKM-1 NWq3c4JQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LvZWlEPTB;MD6wNVY6QSEQvF2= M4Oz[XNCVkeHUh?=
ML-2 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoK5TWM2OD1yLkCxPVg{KM7:TR?= Mn2zV2FPT0WU
BV-173 MmnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDMTXpGUUN3ME2wMlAzOzF2IN88US=> MofCV2FPT0WU
RS4-11 NHf0[5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfjbVdYUUN3ME2wMlAzPTh5IN88US=> MUnTRW5ITVJ?
HL-60 MkPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPwe|JwUUN3ME2wMlAzQTB6IN88US=> MVjTRW5ITVJ?
KY821 NF75N4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\wcWlEPTB;MD6wNlk4PSEQvF2= MVjTRW5ITVJ?
ECC10 MkDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTBwMEO3PVIh|ryP NFnQc2NUSU6JRWK=
NCI-H720 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTBwMESwNVEh|ryP NWn3VZF5W0GQR1XS
QIMR-WIL NHPrZnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTBwMESyPFch|ryP M1PpbHNCVkeHUh?=
KG-1 NWjONZZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7pTWM2OD1yLkC0OFg3KM7:TR?= M1PpSnNCVkeHUh?=
TGW MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnWyTWM2OD1yLkC0OlM{KM7:TR?= NEDpPYNUSU6JRWK=
ATN-1 M4S1[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTBwMES3N|Mh|ryP NUHRR3NMW0GQR1XS
RH-18 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXH3dYFrUUN3ME2wMlA3ODR6IN88US=> MkHDV2FPT0WU
EW-18 M3zoV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkf2TWM2OD1yLkC2PFQyKM7:TR?= MWLTRW5ITVJ?
NB17 M1fnS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLkSnNKSzVyPUCuNFcyOjRizszN NV\zPYNxW0GQR1XS
SK-NEP-1 M2fXV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPpTo5KSzVyPUCuNFczOTNizszN MoLsV2FPT0WU
P12-ICHIKAWA M4Dabmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nLTmlEPTB;MD6wO|c4QCEQvF2= MXzTRW5ITVJ?
KARPAS-45 NIn6[HBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknGTWM2OD1yLkC3PFE2KM7:TR?= NGfuWJJUSU6JRWK=
EW-3 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTrRXRxUUN3ME2wMlA5ODV|IN88US=> NWnaZ2o1W0GQR1XS
NB13 MlXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnZTWM2OD1yLkC4NlA{KM7:TR?= NUjxdmdyW0GQR1XS
NCI-H209 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTBwMEi3NFQh|ryP NHq1R|JUSU6JRWK=
NCI-H1092 M3m4S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHsTWM2OD1yLkGwNlc2KM7:TR?= MV\TRW5ITVJ?
NH-12 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXv6SHFjUUN3ME2wMlExPzR2IN88US=> M{\YUnNCVkeHUh?=
697 MnL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXwTWM2OD1yLkGwPFM6KM7:TR?= MVXTRW5ITVJ?
KE-37 MmjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7oOGZKSzVyPUCuNVE{PyEQvF2= M37ZOHNCVkeHUh?=
MOLT-4 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLFN5BKSzVyPUCuNVUyPjlizszN MkK5V2FPT0WU
CHP-134 NULVbXA6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTBwMU[zNFYh|ryP MULTRW5ITVJ?
D-283MED NIW3cppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDlTWM2OD1yLkG3Olg3KM7:TR?= MkWxV2FPT0WU
LU-135 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\FdWlEPTB;MD6xPFU2OiEQvF2= NWrOc5c2W0GQR1XS
LU-134-A MnLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mom3TWM2OD1yLkG4OlcyKM7:TR?= MXPTRW5ITVJ?
EM-2 NELtXppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHMV|VKSzVyPUCuNVk6OThizszN NXf0S3RnW0GQR1XS
LU-139 Mne2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvvTWM2OD1yLkKwOFk5KM7:TR?= MmLwV2FPT0WU
ALL-PO MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnCeFd1UUN3ME2wMlIyQTh6IN88US=> MVLTRW5ITVJ?
NB12 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mni5TWM2OD1yLkKzNVE2KM7:TR?= NVvzRoRIW0GQR1XS
KP-N-YN M4nY[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHTWHdKSzVyPUCuNlM2PzNizszN MmH4V2FPT0WU
BEN MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknVTWM2OD1yLkKzPVY5KM7:TR?= NWrnVXhkW0GQR1XS
HCC1569 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnCTWM2OD1yLkK1NVA3KM7:TR?= M3LWRnNCVkeHUh?=
HuO9 M3\WSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPudlhTUUN3ME2wMlI3PzF3IN88US=> M2HKb3NCVkeHUh?=
WM-115 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTBwMke3N|gh|ryP MWHTRW5ITVJ?
CCRF-CEM MoHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTpTWM2OD1yLkOzOVI6KM7:TR?= NULQR4o3W0GQR1XS
IST-SL1 MkLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDaRodKSzVyPUCuN|U{PDNizszN MXXTRW5ITVJ?
BE-13 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjUTWM2OD1yLkO2OFU6KM7:TR?= M3PNNHNCVkeHUh?=
COR-L88 M{\qe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLMO|ZqUUN3ME2wMlM3PTRizszN MUHTRW5ITVJ?
DOHH-2 NHzRepNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jhcWlEPTB;MD60NVAzOyEQvF2= NETEb5RUSU6JRWK=
A704 NEi5TnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLyW3hTUUN3ME2wMlQzPjdizszN NUT1[5ZLW0GQR1XS
KNS-81-FD M3T6b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLmN|NzUUN3ME2wMlQ1ODF5IN88US=> NFmwbXFUSU6JRWK=
RPMI-8226 M1zrNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTE[2VVUUN3ME2wMlQ2PjV{IN88US=> NGXCWXJUSU6JRWK=
TGBC24TKB NETGdHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTBwNEW3O|gh|ryP NUfJSVE1W0GQR1XS
NCI-H1304 NIXGZW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTBwNE[xOVch|ryP MULTRW5ITVJ?
MOLT-13 NG\UWlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYmxOnlFUUN3ME2wMlQ3PjF|IN88US=> MY\TRW5ITVJ?
EW-22 NWj1ZVl6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYC1UHVRUUN3ME2wMlQ3PjdzIN88US=> NGfwRpBUSU6JRWK=
MS-1 M{\6emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfCVWNKSzVyPUCuOFY6OzNizszN MoLOV2FPT0WU
RMG-I NF33[YxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIL6fFZKSzVyPUCuOFk1PjRizszN MVPTRW5ITVJ?
NTERA-S-cl-D1 MlHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHDeWdRUUN3ME2wMlUxODF7IN88US=> M{S0[nNCVkeHUh?=
NCI-H1048 M1jwc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTBwNUC5OVMh|ryP MmXkV2FPT0WU
SW1417 NH7aNJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLZVWRKSzVyPUCuOVU1OzhizszN NH3FZVVUSU6JRWK=
DB M1;3emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mme1TWM2OD1yLkW3NFgh|ryP NIXNO5FUSU6JRWK=
MEG-01 MmnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrTTWM2OD1yLkW4N|Ih|ryP MVfTRW5ITVJ?
EW-13 M4\teWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPQXVFKSzVyPUCuOVg{PDFizszN MX3TRW5ITVJ?
LAMA-84 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnCTWM2OD1yLkW5NlA4KM7:TR?= MXrTRW5ITVJ?
J-RT3-T3-5 NWq5V3B{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3q2PWlEPTB;MD62NFgxQCEQvF2= M{OxeHNCVkeHUh?=
MOLT-16 NUn6e|ZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnXTWM2OD1yLk[1NlY1KM7:TR?= MX;TRW5ITVJ?
DU-4475 MlPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTBwNkW0Nlch|ryP NEW3XlRUSU6JRWK=
HAL-01 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DVbmlEPTB;MD63NlU1QSEQvF2= M37LfHNCVkeHUh?=
RD MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7kTWM2OD1yLke1PFk6KM7:TR?= NH24XZpUSU6JRWK=
OAW-28 NHjocWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;jVWRKSzVyPUCuO|g{PyEQvF2= MVvTRW5ITVJ?
HCC38 MkTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{[0c2lEPTB;MD64NFE6KM7:TR?= M3HzZnNCVkeHUh?=
NMC-G1 M2rUZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvrTWM2OD1yLkixNVIyKM7:TR?= M33pS3NCVkeHUh?=
EW-16 NFjjbnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXGTWM2OD1yLkixN|I5KM7:TR?= M{LpNXNCVkeHUh?=
DU-145 MnXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rLN2lEPTB;MD64PVkzOyEQvF2= NXzzeYVNW0GQR1XS
HPAF-II M3vIbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPWbWZPUUN3ME2wMlkzPjJ6IN88US=> MoD3V2FPT0WU
A427 NV31PHhoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnXRolKSzVyPUCuPVMxOjJizszN MVTTRW5ITVJ?
PA-1 MnnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGD6OYxKSzVyPUCuPVU3PDJizszN MX7TRW5ITVJ?
OAW-42 NUjoeYpoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\QSVRKSzVyPUCuPVYyPDZizszN MkfPV2FPT0WU
L-428 NGPFTlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTFwMEGyOUDPxE1? MojaV2FPT0WU
COLO-824 NYH1eIFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTFwMEG3NFgh|ryP NXOxOGtFW0GQR1XS
P30-OHK NVjEZlczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEO0R4dKSzVyPUGuNFQ3QDhizszN MXHTRW5ITVJ?
NCI-H2170 NXnnSXpWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPnTWM2OD1zLkC2NlMh|ryP M1rGSXNCVkeHUh?=
HCC2998 NV3VU5ViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjaclNRUUN3ME2xMlA4OTN3IN88US=> MlXFV2FPT0WU
NB14 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvY[YpHUUN3ME2xMlE{PzR6IN88US=> MXPTRW5ITVJ?
TGBC1TKB NF3ZWJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXoTWM2OD1zLkG0NVUzKM7:TR?= NInnRpdUSU6JRWK=
KP-N-YS M{DRWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HMXGlEPTB;MT6xOlI{PiEQvF2= NU\oZnNxW0GQR1XS
CAL-120 NGX5SJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTFwMU[0Nlkh|ryP M{DzPXNCVkeHUh?=
SBC-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVG1UnlqUUN3ME2xMlE6ODV|IN88US=> MV7TRW5ITVJ?
C32 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzxTWM2OD1zLkG5NFg5KM7:TR?= MmrlV2FPT0WU
HCC2157 MkTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTFwMUm0PVQh|ryP NI\VVnBUSU6JRWK=
COLO-792 NGXpeYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3T0b2lEPTB;MT6yNFA4OSEQvF2= M4nLenNCVkeHUh?=
ES7 NXvsTI5IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rzTmlEPTB;MT6yO|k2OSEQvF2= NFHsTJhUSU6JRWK=
HEL NXnBb5diT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7hTWM2OD1zLkOxNFI6KM7:TR?= NWmyPIlDW0GQR1XS
ES4 M1myNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfSW3pKSzVyPUGuN|Q6QThizszN NXH2fmN5W0GQR1XS
NCI-SNU-1 NHSzcllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTFwM{[1OVUh|ryP MX3TRW5ITVJ?
MDA-MB-415 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTFwM{i4OUDPxE1? NUjIdJBiW0GQR1XS
NCI-H2342 NY\5bpZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTtTWM2OD1zLkSwNlY6KM7:TR?= NUfxe3U2W0GQR1XS
NB69 M2\Bcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfTN3NKSzVyPUGuOFYzPzFizszN MWfTRW5ITVJ?
D-247MG MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPybVFRUUN3ME2xMlUyOTJ{IN88US=> NGPyb5JUSU6JRWK=
SCC-4 NVvITlJJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7KTWM2OD1zLkW5PFg4KM7:TR?= NIPiSIlUSU6JRWK=
HuH-7 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;kcnloUUN3ME2xMlY4Ojl|IN88US=> MUPTRW5ITVJ?
A388 NWDZV41NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfINmdTUUN3ME2xMlY5PzJ2IN88US=> NInjcW9USU6JRWK=
Calu-3 M4rq[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnezTWM2OD1zLkewOlk4KM7:TR?= MnfnV2FPT0WU
NCI-H1648 NEXZVGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorxTWM2OD1zLkexOFE5KM7:TR?= M3\LWXNCVkeHUh?=
NCI-H2052 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPzVnhKSzVyPUGuO|IzODFizszN Ml\GV2FPT0WU
Ramos-2G6-4C10 M{X4d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLFXZJKSzVyPUGuO|M3PTZizszN NY\pNGhMW0GQR1XS
DEL M1zsd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfpWXhKSzVyPUGuO|Q3QTJizszN NUDCRVBRW0GQR1XS
SNU-423 NEHQOoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4K5NmlEPTB;MT63PFE2PyEQvF2= MV;TRW5ITVJ?
COR-L23 Mmi2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzUUHNKSzVyPUGuO|k5PzRizszN NF;1U2hUSU6JRWK=
OMC-1 MlvqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moi3TWM2OD1zLki2NFE3KM7:TR?= MYnTRW5ITVJ?
EW-11 NHXT[IdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXoTWM2OD1zLkm1OlU4KM7:TR?= NVmxUWJ2W0GQR1XS
HSC-3 M4TBfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDETWM2OD1zLkm2N|Y2KM7:TR?= MoTnV2FPT0WU
MLMA MmDsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTNepFKSzVyPUGuPVY3PzdizszN M2[zO3NCVkeHUh?=
RCM-1 M4DSNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF65eXlKSzVyPUKuNFA{QTlizszN Mo\zV2FPT0WU
MFE-280 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nseGlEPTB;Mj6wNlg1QCEQvF2= NGTNVZZUSU6JRWK=
ES8 M4WzVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTJwMkW0O|Eh|ryP M2rUNnNCVkeHUh?=
TE-11 NEPvW|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTJwMkm0O|Mh|ryP NXXVO3NUW0GQR1XS
HuO-3N1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTJwNEi3PEDPxE1? NEnzRlhUSU6JRWK=
MHH-NB-11 MmGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTJwNUGxOVgh|ryP MlHOV2FPT0WU
TGBC11TKB MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rre2lEPTB;Mj61O|Y5OSEQvF2= NYfi[nNkW0GQR1XS
HOP-92 MojCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;wWJJmUUN3ME2yMlU5PzR|IN88US=> MV;TRW5ITVJ?
IGR-1 NFfqeJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDaTWM2OD1{Lk[yNFM2KM7:TR?= MoTiV2FPT0WU
GOTO NE\RNVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXSXINSUUN3ME2yMlY2Ozd5IN88US=> NWfyNmN[W0GQR1XS
NCI-H1650 NX;VPI5IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTJwN{KyNVUh|ryP NXTTOm5sW0GQR1XS
NCI-H1581 MkjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PUUGlEPTB;Mj63PVY5OSEQvF2= NXmzO29{W0GQR1XS
NCI-H2405 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTJwOEK3PFIh|ryP NHXKcnFUSU6JRWK=
U-118-MG Ml2xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoqyTWM2OD1{Lkm2OFkyKM7:TR?= MX;TRW5ITVJ?
DoTc2-4510 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jLN2lEPTB;Mz6wNVQyPyEQvF2= Ml\iV2FPT0WU
NCI-H596 NYLv[G1tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnu1TWM2OD1|LkC0PVk4KM7:TR?= MX7TRW5ITVJ?
MPP-89 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfEPGRtUUN3ME2zMlA2PjZ4IN88US=> MWPTRW5ITVJ?
GCIY NIfNSXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnPb48{UUN3ME2zMlIxPDlzIN88US=> NGjrOG1USU6JRWK=
SW626 NFO4TmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjifIVOUUN3ME2zMlI1PTR|IN88US=> NVLmc21CW0GQR1XS
OCI-AML2 MmrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGe5bZhKSzVyPUOuN|EzPzJizszN MnHuV2FPT0WU
NBsusSR NH:xW|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zuSGlEPTB;Mz6zOFk{QCEQvF2= NI\TPYxUSU6JRWK=
AN3-CA NGDK[IZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\lUYYzUUN3ME2zMlQ1OjN6IN88US=> NVPmRlRqW0GQR1XS
EFM-19 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTNwNEizN|kh|ryP M4DERnNCVkeHUh?=
RVH-421 M1\ZUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TIdWlEPTB;Mz61Olg4PyEQvF2= M1:3dHNCVkeHUh?=
5637 M1LMNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjyTWM2OD1|Lk[xNVA{KM7:TR?= NVztOXBGW0GQR1XS
PANC-08-13 NY\uTItzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTNwNkO0O|Ih|ryP NGDsNFBUSU6JRWK=
H9 NIPkTXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvI[JZQUUN3ME2zMlY4OTR2IN88US=> Ml7HV2FPT0WU
KARPAS-299 NGPiT4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjlTWM2OD1|Lk[3N|YyKM7:TR?= M4XrbnNCVkeHUh?=
TE-5 NYHnfVIyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTNwN{C3NFkh|ryP NGT5[JNUSU6JRWK=
NOS-1 M4fs[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXLTWM2OD1|Lke5PFM1KM7:TR?= NEjKTolUSU6JRWK=
HH NILnTnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETweo9KSzVyPUOuPFM5PjhizszN M4HaeXNCVkeHUh?=
769-P NGnKTmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzwZnhKSzVyPUOuPFk2OSEQvF2= NHzBVWlUSU6JRWK=
CHP-212 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTNwOUK1OFkh|ryP M1izS3NCVkeHUh?=
NCI-H82 MofWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTNwOUW5N|Yh|ryP NHm0SmFUSU6JRWK=
Mo-T MlyyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoT4TWM2OD12LkC0N|EzKM7:TR?= MljUV2FPT0WU
BB65-RCC NH3pV3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLzVlR1UUN3ME20MlA1Ozl7IN88US=> M2DwVHNCVkeHUh?=
SW1990 M{nEUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TlXWlEPTB;ND6wOVkxQCEQvF2= NHjUWYFUSU6JRWK=
LK-2 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTRwMUGyPVMh|ryP NV\SVmpVW0GQR1XS
ES5 NUXNTGt6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHL2RZVKSzVyPUSuNVM6QDVizszN NILIN2RUSU6JRWK=
JVM-3 MmTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHFXmpKSzVyPUSuNVgzOjJizszN MXHTRW5ITVJ?
RPMI-7951 MlnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M162W2lEPTB;ND6yNlQyOyEQvF2= NEXQWHVUSU6JRWK=
Calu-6 NULuN|kyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHz0WmtKSzVyPUSuNlc5QDFizszN MkjtV2FPT0WU
LC-2-ad NFzmb41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTRwMkm1Olgh|ryP NXLIRXZSW0GQR1XS
SW954 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4KyOGlEPTB;ND6yPVY3KM7:TR?= M2Tpc3NCVkeHUh?=
H-EMC-SS NUDwcIVsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn:5TWM2OD12LkOxPFMyKM7:TR?= MX3TRW5ITVJ?
ES3 NEC0Zo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XJbWlEPTB;ND6zOVQ1OSEQvF2= M2XtWnNCVkeHUh?=
no-11 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTRwM{W1OVQh|ryP NVywVnhEW0GQR1XS
LAN-6 M2S5R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTRwNEWxPFkh|ryP NV7uNYw2W0GQR1XS
FTC-133 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jS[GlEPTB;ND61N|k2KM7:TR?= MkL0V2FPT0WU
8505C MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTRwNUSyN{DPxE1? MV\TRW5ITVJ?
SW620 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTITWM2OD12LkW3NFU4KM7:TR?= MYXTRW5ITVJ?
BCPAP MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7xWVRkUUN3ME20MlY{PDhzIN88US=> MVLTRW5ITVJ?
SK-LU-1 NVrLXYJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mli1TWM2OD12Lk[2NFg6KM7:TR?= MmnPV2FPT0WU
NCI-H1623 M4S2eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\vTWM2OD12LkewNlI5KM7:TR?= M{DmcnNCVkeHUh?=
C2BBe1 M3r2ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFv3TGFKSzVyPUSuO|QxODhizszN MlLjV2FPT0WU
GP5d NYjDNFRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLsV5hFUUN3ME20Mlc5Ozh6IN88US=> M1iydHNCVkeHUh?=
NB6 M12zSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnq0TWM2OD12Lki2NlA1KM7:TR?= MUjTRW5ITVJ?
MDA-MB-157 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrG[Ys1UUN3ME20Mlg5PzZizszN M{XjN3NCVkeHUh?=
UMC-11 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLBTWM2OD12Lki4PVY1KM7:TR?= M4nBdXNCVkeHUh?=
HCC1419 NXfsb2hPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDYTWM2OD12LkmwNFY{KM7:TR?= NVPzR45rW0GQR1XS
NCI-H2029 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDC[lFKSzVyPUSuPVQyQDVizszN NGTMU|dUSU6JRWK=
LXF-289 NWnjVJRRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVmy[nVrUUN3ME21MlA{PzF7IN88US=> NFLaXFhUSU6JRWK=
KINGS-1 Ml\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M36wc2lEPTB;NT6wO|c1PCEQvF2= Mnq2V2FPT0WU
HD-MY-Z MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXr6OVBbUUN3ME21MlI{QTZ7IN88US=> NFfrNmxUSU6JRWK=
ESS-1 NFywdHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXywOXV7UUN3ME21MlI2PTl5IN88US=> M3XXXnNCVkeHUh?=
GI-1 NV;oWWJPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\LcmlEPTB;NT6yO|kzPiEQvF2= NHrlV5ZUSU6JRWK=
RPMI-2650 MnzXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTVwM{[xOkDPxE1? M3zhRXNCVkeHUh?=
IA-LM NWXqcFV3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17QXGlEPTB;NT6zPVg4OSEQvF2= MnzjV2FPT0WU
KP-4 NU\KVWdpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlSzTWM2OD13LkS2N|M1KM7:TR?= MV;TRW5ITVJ?
G-402 M1\5W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnaTFdKSzVyPUWuOVE5PjVizszN NFy1SHZUSU6JRWK=
OS-RC-2 NUXW[4dOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HDd2lEPTB;NT61NlYxPCEQvF2= MUDTRW5ITVJ?
NCI-H1155 NVP0OotNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXyNYxDUUN3ME21MlU1QTV3IN88US=> MXPTRW5ITVJ?
OE19 NXi4[XlsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XLV2lEPTB;NT62PFYzPCEQvF2= M1vBTnNCVkeHUh?=
U-2-OS NVm1R5ExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTVwOEmwNVMh|ryP M4e4b3NCVkeHUh?=
SCC-15 M4HUc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HNTGlEPTB;NT65N|Y3OiEQvF2= NIPKPGxUSU6JRWK=
NCI-H630 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTVwOUm0NFQh|ryP NF;0XnhUSU6JRWK=
PFSK-1 NFf2TFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjITWM2OD14LkC1NlU6KM7:TR?= NFT5TmNUSU6JRWK=
NCI-H1770 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\0bGo5UUN3ME22MlIxQDd2IN88US=> NGqxdnBUSU6JRWK=
SK-MEL-3 M1XBPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHkTWM2OD14LkSyPVE2KM7:TR?= MXPTRW5ITVJ?
LB1047-RCC NFHCN3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVftRYVIUUN3ME22MlQ4PjJ3IN88US=> NUT6SXF1W0GQR1XS
NCI-H446 M1jDVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkW2TWM2OD14Lk[yPVI2KM7:TR?= MVTTRW5ITVJ?
SW780 NELZU3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTZwN{CxPFUh|ryP MUXTRW5ITVJ?
NEC8 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPNNlNPUUN3ME22Mlc3PjNizszN M1fse3NCVkeHUh?=
NOMO-1 M3HGRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTZwN{ixNVEh|ryP NGLCSYRUSU6JRWK=
COLO-668 M{W4eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4e1OmlEPTB;Nj64OFM5PyEQvF2= Mm\JV2FPT0WU
MC116 NX[yXG1KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLSTWM2OD14LkmzPFk4KM7:TR?= M2TpUHNCVkeHUh?=
HCC1937 NGHjR3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXr4TmpVUUN3ME22Mlk6OjVzIN88US=> NE\zVINUSU6JRWK=
NCI-N87 Mn;uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfNTWM2OD15LkG5Nlk{KM7:TR?= MoTXV2FPT0WU
COLO-320-HSR MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTqdXZKSzVyPUeuNlI4OzhizszN MWPTRW5ITVJ?
HCC1806 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\zZWlEPTB;Nz6yOlA1PCEQvF2= MUPTRW5ITVJ?
OVCAR-3 M{XsTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHhTWM2OD15LkOzNFM5KM7:TR?= MoS1V2FPT0WU
NUGC-3 NXHMW5BHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;UcIVLUUN3ME23MlM6Pjl2IN88US=> NVjvcFlYW0GQR1XS
SW1783 Mo\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXab5lKSzVyPUeuOFMyPzVizszN NHrHd2JUSU6JRWK=
GCT NFzZOpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTdwNU[5NFYh|ryP NY\XRYRpW0GQR1XS
NCI-H2126 NX\Ibmt5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXiWWpSUUN3ME23Mlc{PjJ3IN88US=> NV7veIZMW0GQR1XS
MEL-HO M2LQWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWO5XmxCUUN3ME23Mlc4ODV2IN88US=> NIfiN5VUSU6JRWK=
CAPAN-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDzTWM2OD15Lke3N|U4KM7:TR?= M4m3WHNCVkeHUh?=
SW756 NIf0O4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTdwN{izN|Mh|ryP NH3JeGtUSU6JRWK=
SKG-IIIa NEX3WIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\qN3VKSzVyPUeuPFE5QTJizszN M1\aOHNCVkeHUh?=
HCE-T NYjKbnpET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXiW|VIUUN3ME23Mlg4Pzh|IN88US=> MkPTV2FPT0WU
Ca-Ski NVvWR2RVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjINpRyUUN3ME23Mlk6Ozh|IN88US=> MkHwV2FPT0WU
COLO-684 M{PJSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjSVVlKSzVyPUiuNFE5OThizszN NGTmeFVUSU6JRWK=
KYSE-70 M4nEVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvwZVdKSzVyPUiuNFc4OjlizszN NXf6c3pMW0GQR1XS
TI-73 M{X5Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4O4VWlEPTB;OD6yOVg2OSEQvF2= MmqxV2FPT0WU
BT-20 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fiWGlEPTB;OD6yOlA2OiEQvF2= M2W5fXNCVkeHUh?=
MHH-ES-1 M1S2Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRThwNUG4N|Qh|ryP NInEfmpUSU6JRWK=
TE-12 M1n1bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2j1TWlEPTB;OD61PVk{OSEQvF2= M1XJdnNCVkeHUh?=
YH-13 NES5c4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRThwNkGwNFgh|ryP Mk\jV2FPT0WU
SF126 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3ncVNKSzVyPUiuPFM5PjVizszN MkW0V2FPT0WU
J82 NGfsR5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PmU2lEPTB;OD65NFA{QCEQvF2= M{PJenNCVkeHUh?=
RCC10RGB MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnvTYhbUUN3ME24Mlk6PTZzIN88US=> M4nCd3NCVkeHUh?=
SK-UT-1 NELiWG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLqTWM2OD17LkC0PVQ2KM7:TR?= MonkV2FPT0WU
LB2241-RCC NYryPVBXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fNXWlEPTB;OT6xPVE{PyEQvF2= MWjTRW5ITVJ?
LB996-RCC MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3lUZNKSzVyPUmuNVk5QSEQvF2= NHLXUopUSU6JRWK=
EPLC-272H NXTP[IZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrVeVlDUUN3ME25MlM4PjV5IN88US=> MknhV2FPT0WU
CTV-1 NG\LNYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXyzdm1tUUN3ME25MlU3PTN{IN88US=> MoLjV2FPT0WU
HSC-2 NFztOm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkmyTWM2OD17LkW3OVUh|ryP NW\XcoJZW0GQR1XS
SK-MEL-28 NELHR2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4WyPWlEPTB;OT62NVg6OyEQvF2= MnLkV2FPT0WU
MMAC-SF MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTlwNki3OUDPxE1? NX\uW5dCW0GQR1XS
CP50-MEL-B MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEe0UpdKSzVyPUmuO|U4QDJizszN MYXTRW5ITVJ?
HT-1080 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHlNllKSzVyPUmuO|c4OzlizszN MXXTRW5ITVJ?
HEC-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoW1TWM2OD1zMD6zN|UzKM7:TR?= NIPQXYZUSU6JRWK=
AGS MlzJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTFyLkO3OEDPxE1? M{fsXXNCVkeHUh?=
GAMG NWTYeGhET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1uxZ2lEPTB;MUCuOVE3OiEQvF2= NF;WSW5USU6JRWK=
SW48 M{HhR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLUTWM2OD1zMD61NVg6KM7:TR?= MojTV2FPT0WU
U031 M1P4VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTFyLkW5NFgh|ryP MmHJV2FPT0WU
OVCAR-5 NX\hO4NKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnrVmdKSzVyPUGwMlY1OjlizszN MVLTRW5ITVJ?
SF295 NH\E[llIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HNdWlEPTB;MUCuOlcxPCEQvF2= M33p[nNCVkeHUh?=
BHT-101 M{jaWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIruZ2JKSzVyPUGwMlcyPzdizszN NYLsNldoW0GQR1XS
VMRC-RCZ MluzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjBTJJKSzVyPUGxMlMzODFizszN M1zZSnNCVkeHUh?=
ACHN NGf1V2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGG1PWdKSzVyPUGxMlQzOTFizszN NYWyc5R{W0GQR1XS
NCI-H526 M{DRUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rRfWlEPTB;MUGuOVA1OyEQvF2= NF[1NXJUSU6JRWK=
MN-60 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHP0OlZKSzVyPUGxMlU{QSEQvF2= M3LtOXNCVkeHUh?=
NCI-H2291 NXyyNYNXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPjcYJkUUN3ME2xNU42PDZ4IN88US=> M4\qfXNCVkeHUh?=
SCC-25 MoXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrJ[pdWUUN3ME2xNU44PTV4IN88US=> M{HNdHNCVkeHUh?=
SK-MEL-2 NVH6XZRQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLvTWM2OD1zMT63OlM4KM7:TR?= NYC1[3B4W0GQR1XS
SN12C NVyx[WVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TRPWlEPTB;MUGuPVM2PSEQvF2= M3;V[3NCVkeHUh?=
NCI-H69 NUHnenBPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH:2NplKSzVyPUGyMlQzOzRizszN NWfWWWpRW0GQR1XS
ME-180 M3LQZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjjcGtKSzVyPUGyMlcxPTRizszN NE\QXWRUSU6JRWK=
MC-IXC MoG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTF{Lke1NVgh|ryP M1nlTnNCVkeHUh?=
NCI-H2347 Mn2zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXE[WtKSzVyPUGyMlc3OTRizszN MmPyV2FPT0WU
M059J MkPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonGTWM2OD1zMj63O|I4KM7:TR?= NEjueYJUSU6JRWK=
A2058 M3HoSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTF{Lki2PFEh|ryP NGjQeYlUSU6JRWK=
VA-ES-BJ MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHyNZdKSzVyPUGyMlg4QDVizszN Ml[2V2FPT0WU
Ca9-22 NVPGSotvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTF{Lkm0OVEh|ryP MoPRV2FPT0WU
KNS-42 NW[ySZZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfleWhWUUN3ME2xNk46QTh2IN88US=> NELtWFJUSU6JRWK=
LoVo M1\o[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnEdG9KSzVyPUGzMlI{OTNizszN MX;TRW5ITVJ?
AM-38 NWHNe|hqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUP4OFk1UUN3ME2xN{4zPTZ4IN88US=> M{jkb3NCVkeHUh?=
NB5 MmjNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M163fWlEPTB;MUOuN|c2OiEQvF2= MWfTRW5ITVJ?
L-363 NX3xem5GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknjTWM2OD1zMz60NFM{KM7:TR?= MYDTRW5ITVJ?
SK-MEL-30 NEHJUYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojqTWM2OD1zND6wOlQ2KM7:TR?= Mlm4V2FPT0WU
NCI-H1563 NEntVXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\qTWM2OD1zND62NFM6KM7:TR?= MonNV2FPT0WU
NCI-H2228 NHLGN2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTF2Lk[wO|ch|ryP NIHXTIJUSU6JRWK=
MFM-223 M1vjW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7GbHBKSzVyPUG1MlE5OTNizszN MonJV2FPT0WU
LB831-BLC NYrpTG5mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFO0[ZpKSzVyPUG1MlI4PjdizszN MkXDV2FPT0WU
SW872 NYfuRVhwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInlU|NKSzVyPUG1MlMxQDZizszN NIXke4pUSU6JRWK=
NCI-H522 NEXjd|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\lTWM2OD1zNT6zN|A3KM7:TR?= NGP1NppUSU6JRWK=
EW-1 NUnlW5Q6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPxTWM2OD1zNT61OFYzKM7:TR?= M{K2NHNCVkeHUh?=
HN MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjtVo0zUUN3ME2xOU42QTR{IN88US=> NGjzXmdUSU6JRWK=
SW837 Mlz0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jwcmlEPTB;MUWuO|g1PyEQvF2= M1jTRnNCVkeHUh?=
SCC-9 M{XqNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHaOHNoUUN3ME2xOU45OTF2IN88US=> Mlz3V2FPT0WU
MKN7 M{HtPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTF3Lkm3N|Ih|ryP M1rTdnNCVkeHUh?=
KYSE-410 NHXGRVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTF4LkW5NUDPxE1? Mm\iV2FPT0WU
SK-N-DZ M4i3OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXCeJVSUUN3ME2xOk43OTF4IN88US=> M3\HdHNCVkeHUh?=
COR-L105 Mn\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnoeIVKSzVyPUG2MlY2OjhizszN MWDTRW5ITVJ?
LB2518-MEL M1niN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXHZWNKSzVyPUG2Mlg{QDlizszN Mo\2V2FPT0WU
OVCAR-4 NYroblRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzMTWM2OD1zNj64PFYzKM7:TR?= NHjpXVJUSU6JRWK=
TK10 MoOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jDemlEPTB;MU[uPVQ4OyEQvF2= M{TmOnNCVkeHUh?=
KNS-62 MmH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1SwemlEPTB;MU[uPVc4PyEQvF2= M4HMb3NCVkeHUh?=
RPMI-8866 Ml7hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PUNmlEPTB;MUeuNVc{OiEQvF2= MoD0V2FPT0WU
HuP-T4 MmXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzz[Id6UUN3ME2xO{4zPDl3IN88US=> MlfkV2FPT0WU
CGTH-W-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjkOW9TUUN3ME2xO{42OjF7IN88US=> NUC2fGV[W0GQR1XS
T-24 NE\yeFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXWOGo2UUN3ME2xO{42OzR5IN88US=> NHGxPIZUSU6JRWK=
HT-3 NXLzXpJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4ntR2lEPTB;MUeuOVkyPCEQvF2= M4nEbXNCVkeHUh?=
KS-1 NEjBT5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PxNmlEPTB;MUeuOlc{KM7:TR?= NIfwTnVUSU6JRWK=
NCI-H1792 NXvLSFQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17iVWlEPTB;MUeuO|k5KM7:TR?= NIO5enlUSU6JRWK=
ABC-1 MkTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTF5LkixOFEh|ryP NUW5fY04W0GQR1XS
BPH-1 MlzRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7GdGZPUUN3ME2xPE4yPjh3IN88US=> M{TRZXNCVkeHUh?=
A431 NEniSopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4m2O2lEPTB;MUiuOFEzPyEQvF2= MlLRV2FPT0WU
T98G NGnP[mNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTF6LkWxOVch|ryP NF7OSplUSU6JRWK=
BHY NGX1ZodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnqxTWM2OD1zOD64Olkh|ryP NHewU|VUSU6JRWK=
Capan-2 M1O2Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnm2TWM2OD1zOD65NFc5KM7:TR?= NXHYRpVIW0GQR1XS
MDA-MB-175-VII NH:wUGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3pWpZKSzVyPUG4MlkzODlizszN NXfkNmlyW0GQR1XS
CAL-27 NXe3T5VvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIn2UXpKSzVyPUG5MlA1QDdizszN Mn32V2FPT0WU
AsPC-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTF7Lki2OVch|ryP MoDQV2FPT0WU
KU812 M3\V[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGO2cYZKSzVyPUG5Mlk2PzNizszN MlXKV2FPT0WU
NCI-H441 NFfJUGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTJyLkCwNUDPxE1? NHLCS|ZUSU6JRWK=
Mewo NITkT3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTJyLkGyPFgh|ryP Mn3UV2FPT0WU
SK-MEL-24 Mo\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLaTWM2OD1{MD6xOFc4KM7:TR?= MkLMV2FPT0WU
NCI-H727 NUeycIJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rtcmlEPTB;MkCuNlcxPCEQvF2= MXTTRW5ITVJ?
EKVX NX63UIh6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;HVmhyUUN3ME2yNE43ODZizszN MmL3V2FPT0WU
RT-112 NYDYfFlIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVeyV3dQUUN3ME2yNE43OTJ{IN88US=> M{Lk[3NCVkeHUh?=
CAMA-1 M1[xUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInvS5dKSzVyPUKwMlk5ODNizszN NEe0eoRUSU6JRWK=
SW900 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTJzLkCxOFkh|ryP M{HrVHNCVkeHUh?=
NCI-H23 MoHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTJzLkGyO|ch|ryP MmPHV2FPT0WU
SK-PN-DW NXS2c|RCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTJzLkG2OFkh|ryP NFzIfVhUSU6JRWK=
BB30-HNC NX3LbZdHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkSxTWM2OD1{MT6yO|Q2KM7:TR?= MYPTRW5ITVJ?
VM-CUB-1 MoHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTJzLkO1N|Yh|ryP NX2yUWlFW0GQR1XS
IST-MEL1 NYXRXVZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjIc|VPUUN3ME2yNU4{Pjl{IN88US=> NGDwflFUSU6JRWK=
CTB-1 NYK1TJc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkP1TWM2OD1{MT60O|U2KM7:TR?= Ml3zV2FPT0WU
LCLC-103H M2nFUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1L0c2lEPTB;MkKuNVU5OiEQvF2= Mm\SV2FPT0WU
PANC-03-27 NIHDNVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2f1NGlEPTB;MkKuOVE3QSEQvF2= MYrTRW5ITVJ?
HTC-C3 NVjjT4oyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1mxeGlEPTB;MkKuOVU2PSEQvF2= MlSzV2FPT0WU
TE-8 NIrOWItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTJ|LkK1OlUh|ryP MnvpV2FPT0WU
NCI-H292 M2SxSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3j3UmlEPTB;MkWuN|U{PiEQvF2= NGjwXXZUSU6JRWK=
COLO-680N NUf0XlZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jLVmlEPTB;MkWuOlMzQSEQvF2= NF3pW4JUSU6JRWK=
KYSE-520 M3TuXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDXZoVnUUN3ME2yOU43PDRizszN M{fkenNCVkeHUh?=
NB10 NWPSRYFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTJ4LkOxNVch|ryP MkH6V2FPT0WU
NCI-H661 NUTDdFJCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnlTWM2OD1{Nj60O|E{KM7:TR?= MVjTRW5ITVJ?
GMS-10 NGW2XoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTJ4Lki2N|gh|ryP NX\EPXBQW0GQR1XS
NCI-H2122 M2TGdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnhXG9KSzVyPUK2Mlk6QThizszN NV;vT4VbW0GQR1XS
OVCAR-8 NET3U5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHOZlFtUUN3ME2yO{4xPjN6IN88US=> M3W5VXNCVkeHUh?=
DJM-1 NVXqZm5mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTJ5LkG0OVQh|ryP MmW2V2FPT0WU
UACC-893 M1Hi[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrkPYxMUUN3ME2yO{46QDd6IN88US=> M1WyZnNCVkeHUh?=
C8166 MmfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\BZ2lEPTB;MkiuOlk{QCEQvF2= MoW1V2FPT0WU
NCI-H1693 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIq1VWFKSzVyPUK4MlY6PzVizszN MXjTRW5ITVJ?
TYK-nu M2XXUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;rTWM2OD1|MD6wN|Q2KM7:TR?= MmPSV2FPT0WU
SW1710 MonOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUSyR2FqUUN3ME2zNE4yOjZizszN NXi5NY9HW0GQR1XS
A375 MlvxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDJRY5pUUN3ME2zNE4{OjR|IN88US=> NGixU2VUSU6JRWK=
HMV-II NUXGbXZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLzW5M5UUN3ME2zNU4{PTl{IN88US=> NHm2Um1USU6JRWK=
NCI-H2087 NVj5O41QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTNzLk[zOVIh|ryP NFjZNnZUSU6JRWK=
CAL-54 M4XVZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULubos4UUN3ME2zNU44OjRzIN88US=> M{T6[nNCVkeHUh?=
HCC70 NHH2TmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTN{LkGzPFch|ryP M13lOnNCVkeHUh?=
ES1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlK5TWM2OD1|Mj6zNFYzKM7:TR?= M13DdHNCVkeHUh?=
NCI-H1355 NHq2T5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLJfJZpUUN3ME2zN{4zODRizszN NXSzbYd5W0GQR1XS
CFPAC-1 NE[0fXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHMR29KSzVyPUOzMlI{OzJizszN M124VnNCVkeHUh?=
MKN28 NUPrN2JnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGr6SWpKSzVyPUOzMlM5ODlizszN NXi4WGFVW0GQR1XS
HDLM-2 NID3WFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPQTWM2OD1|Mz62PVMyKM7:TR?= MYjTRW5ITVJ?
PANC-10-05 M4LCZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjCZ3dKSzVyPUO0MlExOTRizszN NXPaRZZ2W0GQR1XS
SAS M33nWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfxTWM2OD1|ND60OVY2KM7:TR?= NHHES4tUSU6JRWK=
HCC1395 NYnuN|ZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLvS2NKSzVyPUO0MlcyQDZizszN NG\SSm5USU6JRWK=
8305C MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrwTWM2OD1|NT64OFE2KM7:TR?= MX3TRW5ITVJ?
KM12 NHnUPWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV2zNYpnUUN3ME2zOk44PTR5IN88US=> NH;MNHJUSU6JRWK=
SW1116 NHT5V4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nsc2lEPTB;M{euOVk6OiEQvF2= NWPMWolXW0GQR1XS
SK-MEL-1 MlvpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;jNIFKSzVyPUO4MlM{QDlizszN M1jQcHNCVkeHUh?=
HCC2218 NU\2V2k{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{D3cGlEPTB;M{iuOlUyQSEQvF2= MmLSV2FPT0WU
T84 MlLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPmRnAzUUN3ME2zPE44PDB7IN88US=> NUXkPVl6W0GQR1XS
ETK-1 MoPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2W0OWlEPTB;M{muNFIzKM7:TR?= NE\iR3JUSU6JRWK=
COLO-800 M{j6Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzx[otRUUN3ME2zPU4{QDZ6IN88US=> MmjLV2FPT0WU
CAL-12T NILCbZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTN7LkWyPFEh|ryP NECzbIVUSU6JRWK=
ACN NVLvUWd6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLyWmhoUUN3ME20NE41QTFzIN88US=> MoPJV2FPT0WU
SJSA-1 MnXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLrTWM2OD12MT6xOVk3KM7:TR?= NGPId41USU6JRWK=
PSN1 NFzKWIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmWwTWM2OD12MT6xO|Q6KM7:TR?= NXTsfIZ7W0GQR1XS
D-566MG M4mzeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTRzLkKwPFYh|ryP MlHKV2FPT0WU
EGI-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDTOnZ{UUN3ME20Nk41OjhizszN M2jTdXNCVkeHUh?=
A204 Ml7aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4C2ZmlEPTB;NEKuOlM5QCEQvF2= M1TBdnNCVkeHUh?=
Saos-2 M2XKT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHufZdKSzVyPUSyMlg{PjlizszN M4D4TXNCVkeHUh?=
SNU-C2B NIDNc4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnjVIZ4UUN3ME20N{43QDd6IN88US=> MoHCV2FPT0WU
HLE NF\WXodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;KOGlEPTB;NESuNFg2PiEQvF2= NHzKU2RUSU6JRWK=
SW1463 MnvjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHyN|RKSzVyPUS0Mlk6PzFizszN NVrpbINiW0GQR1XS
DSH1 NXSzeoc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTuVXhKSzVyPUS1MlAxOzNizszN MUnTRW5ITVJ?
MCF7 NV35dWhJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTR3LkWwOVEh|ryP NXTzVJpmW0GQR1XS
K5 NWLI[mdIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHKeYNKSzVyPUS1Mlk1ODVizszN MXvTRW5ITVJ?
NCI-H358 M{fSW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoH0TWM2OD12Nz6yNVUh|ryP MmjTV2FPT0WU
NCI-H2030 NGLUPFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\DTWM2OD12Nz6yN|c1KM7:TR?= NX7r[I9QW0GQR1XS
SW948 Ml\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3TTWM2OD12Nz60OlQh|ryP NUjSdotDW0GQR1XS
BALL-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLmTWM2OD12Nz62NVY5KM7:TR?= MU\TRW5ITVJ?
TE-9 MmjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zLNGlEPTB;NEeuPVU5OSEQvF2= M1LTPXNCVkeHUh?=
SK-N-FI MlG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rseWlEPTB;NEiuNFM2QCEQvF2= M1fKSnNCVkeHUh?=
KALS-1 NV3hOlNiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTR6LkGyPFkh|ryP NXW4UlhNW0GQR1XS
HO-1-N-1 NUXP[YYxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojOTWM2OD12OD63OFQ2KM7:TR?= NYLDb4p1W0GQR1XS
NCI-H2452 M4\idWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTR7LkGxOVIh|ryP M1i2[HNCVkeHUh?=
OC-314 M3vSdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTR7Lk[4N|Qh|ryP MYHTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo When ABT-263 is administered at 100 mg/kg/day in the H345 xenograft model, significant antitumor efficacy is observed with 80% TGI and 20% of treated tumors indicating at least a 50% reduction in tumor volume. [2] Oral administration of ABT-263 alone causes complete tumor regressions in xenograft models of small-cell lung cancer and acute lymphoblastic leukemia. In xenograft models of aggressive B-cell lymphoma and multiple myeloma where ABT-263 displays modest or no single agent activity, it significantly enhances the efficacy of clinically relevant therapeutic regimens. [2]

Protocol

Kinase Assay:

[1]

+ Expand

Affinity determination:

Binding affinities (Ki or IC50) of ABT-263 against different isoforms of Bcl-2 family are determined with competitive fluorescence polarization assays. The following peptide probe/protein pairs are used: f-bad (1 nM) and Bcl-xL (6 nM), f-Bax (1 nM) and Bcl-2 (10 nM), f-Bax (1 nM) and Bcl-w (40 nM), f-Noxa (2 nM) and Mcl-1 (40 nM), and f-Bax (1 nM) and Bcl-2-A1 (15 nM). Binding affinities for Bcl-xL are also determined using a time-resolved fluorescence resonance energy transfer assay. Bcl-xL (1 nM, His tagged) is mixed with 200 nM f-Bak, 1 nM Tb-labeled anti-His antibody, and ABT-263 at room temperature for 30 min. Fluorescence is measured on an Envision plate reader using a 340/35 nm excitation filter and 520/525 (f-Bak) and 495/510 nm (Tb-labeled anti-His antibody) emission filters.
Cell Research:

[1]

+ Expand
  • Cell lines: SCLC cell lines
  • Concentrations: 0-1 μM
  • Incubation Time: 48 hours
  • Method:

    Human tumor cell lines SCLC cell lines are maintained at 37℃ containing 5% CO2. SCLC cell lines are cultured in RPMI 1640 with 10% fetal bovine serum (FBS), 1% sodium pyruvate, 25 mM HEPES, 4.5 g/L glucose, and 1% penicillin/streptomycin. Leukemia and lymphoma cell lines are cultured in RPMI 1640 supplemented with 10% FBS and 1% penicillin/streptomycin. Cells (1-5×10 4) are treated by ABT-263 for 48 hours in 96-well culture plates in a final volume of 100 μL and cytotoxicity is assessed with the CellTiter Glo assay. In vitro cyto toxicity of ABT-263 is assayed.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: C.B.-17 scid-bg or C.B.-17 scid mice
  • Formulation: Formulated in 10% ethanol, 30% polyethylene glycol 400, and 60% Phosal 50 PG
  • Dosages: 100 mg/kg/d
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (102.6 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 5% DMSO+corn oil 7mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 974.61
Formula

C47H55ClF3N5O6S3

CAS No. 923564-51-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02520778 Recruiting EGFR Activating Mutation|Recurrent Non-Small Cell Lung Carcinoma|Stage III Non-Small Cell Lung Cancer|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer National Cancer Institute (NCI) March 2016 Phase 1
NCT02591095 Active, not recruiting Platinum-resistant or Refractory Ovarian Cancer Centre Francois Baclesse|ARCAGY/ GINECO GROUP|French Cancer Research Hospital Program January 2016 Phase 2
NCT02143401 Recruiting Recurrent Hepatocellular Carcinoma|Solid Neoplasm|Stage IV Hepatocellular Carcinoma National Cancer Institute (NCI) November 2014 Phase 1
NCT02079740 Recruiting Advanced Solid Neoplasm|KRAS Gene Mutation|Metastatic Solid Neoplasm|NRAS Gene Mutation|Recurrent Colorectal Carcinoma|Recurrent Lung Carcinoma|Recurrent Pancreatic Carcinoma|Stage III Colorectal Cancer|Stage III Lung Cancer|Stage III Pancreatic Cancer|Stage IIIA Colorectal Cancer|Stage IIIB Colorectal Cancer|Stage IIIC Colorectal Cancer|Stage IV Colorectal Cancer|Stage IV Lung Cancer|Stage IV Pancreatic Cancer|Stage IVA Colorectal Cancer|Stage IVB Colorectal Cancer National Cancer Institute (NCI) March 2014 Phase 1|Phase 2
NCT01989585 Recruiting Metastatic Melanoma|Recurrent Melanoma|Solid Neoplasm|Stage IIIA Skin Melanoma|Stage IIIB Skin Melanoma|Stage IIIC Skin Melanoma|Stage IV Skin Melanoma National Cancer Institute (NCI) October 2013 Phase 1|Phase 2
NCT01828476 Completed Prostate Cancer Rutgers, The State University of New Jersey|Rutgers Cancer Institute of New Jersey|National Cancer Institute (NCI)|AbbVie June 2013 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products

Tags: buy ABT-263 (Navitoclax) | ABT-263 (Navitoclax) supplier | purchase ABT-263 (Navitoclax) | ABT-263 (Navitoclax) cost | ABT-263 (Navitoclax) manufacturer | order ABT-263 (Navitoclax) | ABT-263 (Navitoclax) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID